These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32418993)

  • 1. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Cheung VTF; Gupta T; Olsson-Brown A; Subramanian S; Sasson SC; Heseltine J; Fryer E; Collantes E; Sacco JJ; Pirmohamed M; Simmons A; Klenerman P; Tuthill M; Protheroe AS; Chitnis M; Fairfax BP; Payne MJ; Middleton MR; Brain O
    Br J Cancer; 2020 Jul; 123(2):207-215. PubMed ID: 32418993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
    Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.
    Mohammed Vashist N; Samaan M; Mosli MH; Parker CE; MacDonald JK; Nelson SA; Zou GY; Feagan BG; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011450. PubMed ID: 29338066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
    Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
    J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis.
    Abu-Sbeih H; Ali FS; Luo W; Qiao W; Raju GS; Wang Y
    J Immunother Cancer; 2018 Sep; 6(1):95. PubMed ID: 30253811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.
    Geukes Foppen MH; Rozeman EA; van Wilpe S; Postma C; Snaebjornsson P; van Thienen JV; van Leerdam ME; van den Heuvel M; Blank CU; van Dieren J; Haanen JBAG
    ESMO Open; 2018; 3(1):e000278. PubMed ID: 29387476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.
    Singh BP; Marshall JL; He AR
    Oncologist; 2020 Mar; 25(3):197-202. PubMed ID: 32162824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis.
    Corte C; Fernandopulle N; Catuneanu AM; Burger D; Cesarini M; White L; Keshav S; Travis S
    J Crohns Colitis; 2015 May; 9(5):376-81. PubMed ID: 25770163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
    Lesage C; Longvert C; Prey S; Maanaoui S; Dréno B; Machet L; Zehou O; Kramkimel N; Jeudy G; Skowron F; Aubin F; Visseaux L; Mansard S; Dereure O; Lesage FX; Guillot B;
    J Immunother; 2019 Jun; 42(5):175-179. PubMed ID: 31090656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
    Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
    Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score.
    Ikeya K; Hanai H; Sugimoto K; Osawa S; Kawasaki S; Iida T; Maruyama Y; Watanabe F
    J Crohns Colitis; 2016 Mar; 10(3):286-95. PubMed ID: 26581895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.
    Pisuchpen N; Durbin SM; Mooradian MJ; Fintelmann FJ; Reynolds KL; Dougan M; Kambadakone A
    Eur Radiol; 2021 Dec; 31(12):8868-8878. PubMed ID: 34081152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity.
    de Jong DC; Löwenberg M; Koumoutsos I; Ray S; Mawdsley J; Anderson S; Sanderson JD; Gecse K; Ponsioen CY; D'Haens GR; Irving PM; Samaan MA
    Inflamm Bowel Dis; 2019 Apr; 25(5):937-944. PubMed ID: 30329045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
    Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.